Latest News

Eris-Natco tie-up to launch semaglutide generic as India market heats up

February 24, 2026 at 04:45 PM
By Business Standard India
Eris-Natco tie-up to launch semaglutide generic as India market heats up
Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies

đŸ’¡Analysis & Context

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense Monitor developments in Eris-Natco for further updates.

đŸ“‹ Quick Summary

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as risin

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies
Share:

Help us improve this article. Share your feedback and suggestions.

Related Articles

Cookie Consent

We use cookies to enhance your browsing experience, analyze site traffic, and serve personalized ads. By clicking "Accept", you consent to our use of cookies. You can learn more about our cookie practices in our Privacy Policy.